Published in Prostate on March 01, 2008
NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res (Phila) (2011) 1.21
GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. J Urol (2014) 1.12
Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res (2009) 1.06
Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci (2014) 1.05
The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Mol Cell Biol (2010) 0.94
MicroRNA 329 suppresses angiogenesis by targeting CD146. Mol Cell Biol (2013) 0.93
Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples. Biomark Cancer (2010) 0.91
Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells. Bioorg Med Chem Lett (2011) 0.90
TGF-β mediated DNA methylation in prostate cancer. Transl Androl Urol (2012) 0.85
Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine. Oncotarget (2014) 0.83
Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China. Oncotarget (2015) 0.77
Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors. Oncogene (2016) 0.77
Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile. Future Oncol (2014) 0.76
Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients. Oncotarget (2017) 0.75
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature (2011) 4.84
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. Nat Genet (2010) 3.66
Functional genomic screen for modulators of ciliogenesis and cilium length. Nature (2010) 3.63
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat (2007) 2.49
TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia (2006) 2.48
DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46
DNA methylation markers in colorectal cancer. Cancer Metastasis Rev (2010) 2.40
Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res (2004) 2.34
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res (2006) 2.29
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol (2006) 2.19
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19
Laparoscopy-assisted pancreas- and spleen-preserving total gastrectomy for gastric cancer as compared with open total gastrectomy. Surg Endosc (2009) 2.12
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res (2002) 1.97
Analysis of the ganglion cell layer and photoreceptor layer using optical coherence tomography after idiopathic epiretinal membrane surgery. Graefes Arch Clin Exp Ophthalmol (2014) 1.97
Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76
Evolutionarily assembled cis-regulatory module at a human ciliopathy locus. Science (2012) 1.74
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res (2011) 1.71
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Secretome analysis reveals an Arabidopsis lipase involved in defense against Alternaria brassicicola. Plant Cell (2005) 1.68
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci U S A (2003) 1.66
Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res (2003) 1.65
Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol (2005) 1.63
Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res (2010) 1.62
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res (2003) 1.59
Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Res (2003) 1.59
Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics (2010) 1.57
Mitochondrial subversion in cancer. Cancer Prev Res (Phila) (2011) 1.54
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 1.54
Designed fabrication of multifunctional magnetic gold nanoshells and their application to magnetic resonance imaging and photothermal therapy. Angew Chem Int Ed Engl (2006) 1.54
Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer (2010) 1.53
Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res (2002) 1.53
Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle (2013) 1.52
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51
DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell (2002) 1.51
Magnetic fluorescent delivery vehicle using uniform mesoporous silica spheres embedded with monodisperse magnetic and semiconductor nanocrystals. J Am Chem Soc (2006) 1.51
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47
Mouse mammary tumor-like env gene as a molecular marker for breast cancer? Int J Cancer (2002) 1.47
Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res (2002) 1.46
Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardiovasc Surg (2002) 1.46
Involvement of aquaporins in colorectal carcinogenesis. Oncogene (2003) 1.45
Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev (2004) 1.45
Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer (2005) 1.45
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45